XML 60 R26.htm IDEA: XBRL DOCUMENT

Subsequent Events Subsequent Events (Notes)	6 Months Ended
Subsequent Events Subsequent Events (Notes)	Jun. 30, 2018
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events AliveGen Inc. In July 2018 we acquired ALG-801 (Phase 1a) and ALG-802 (preclinical) from AliveGen Inc. (AliveGen). ALG-801 (now known as BIIB110) and ALG-802 represent novel ways of targeting the myostatin pathway. We initially plan to study BIIB110 and ALG-802 in multiple neuromuscular indications including SMA and ALS. In connection with the closing of this transaction, we made an upfront payment of $27.5 million to AliveGen and we may pay AliveGen up to $535.0 million in additional potential development and commercialization milestones across both assets and multiple indications.